Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Stock Information for Evogene Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evogene Ltd.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Evogene Reports Second Quarter and First Half 2026 Financial Results
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag(TM) Capabilities
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI(TM) Toward Autonomous Small Molecule Discovery and Optimization

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.